Natco Pharma gets EIR from USFDA for Kothur facility

The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company's drug formulations facility in Kothur, Natco Pharma said in a BSE filing.

PTI

August 05, 2019 / 01:40 PM IST

live

bselive
nselive

Volume

Todays L/H

Drug firm Natco Pharma on Monday said it has received establishment inspection report (EIR) from the US health regulator for its Kothur facility in Telangana.

The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company's drug formulations facility in Kothur, Natco Pharma said in a BSE filing.

The plant was inspected from May 30 to June 5, 2019, it added.

Shares of Natco Pharma were trading at Rs 526.75 per scrip on the BSE, down 0.08 per cent from its previous close.

PTI

Tags: #Business #Companies

first published: Aug 5, 2019 01:36 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Invest in Commercial Real Estate Fractionally

Expert Trading Guidance

Natco Pharma gets EIR from USFDA for Kothur facility

The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company's drug formulations facility in Kothur, Natco Pharma said in a BSE filing.